Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | ALPG | P10696 | 1/20 | 0.34 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL31038510 | 0.89 | ACHE (0.36) | ACHEMEN1GAAMAPK1KMT2A | |
| SCHEMBL11030024 | 0.85 | ACHE (0.42) | ACHEMEN1GAAMAPK1KMT2A | |
| SCHEMBL31139293 | 0.85 | ACHE (0.42) | ACHEMEN1GAAMAPK1KMT2A | |
| SCHEMBL31039215 | 0.84 | ACHE (0.36) | ACHEMEN1GAAMAPK1KMT2A | |
| SCHEMBL501235 | 0.84 | RECQL (0.45) | ACHEMEN1GAAMAPK1KMT2A | |
| SCHEMBL17656587 | 0.84 | ACHE (0.36) | ACHEMEN1GAAMAPK1KMT2A | |
| SCHEMBL1828814 | 0.84 | NOS2 (0.52) | ACHEMEN1GAAMAPK1KMT2A | |
| SCHEMBL568443 | 0.84 | ACHE (0.36) | ACHEMEN1GAAMAPK1KMT2A | |
| SCHEMBL2747792 | 0.82 | NOS3 (0.39) | ACHEMEN1GAAMAPK1KMT2A | |
| SCHEMBL1620417 | 0.80 | ALDH1A1 (0.42) | MEN1KMT2AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | claimed |
| US-12570666-B2 | Furoindazole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2026-03-10 | — | — | US | disclosed |
| EP-4126835-B1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12516038-B2 | Inhibitors of antigen presentation by HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-06 | — | — | US | disclosed |
| US-12421224-B2 | Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4077334-B1 | FUROINDAZOLE DERIVATIVES | BAYER AG (DE) | 2025-03-12 | — | — | EP | disclosed |
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| CN-115135656-B | Furanoindazole derivatives | 拜耳公司 | 2024-06-14 | — | — | CN | disclosed |
| US-11827620-B2 | Compounds and uses thereof for detection of target molecules in a sample | UNIVERSITE DE GENEVE (CH) | 2023-11-28 | — | — | US | disclosed |
| US-11827620-B2 | Compounds and uses thereof for detection of target molecules in a sample | UNIVERSITE DE GENEVE (CH) | 2023-11-28 | — | — | US | disclosed |
| WO-1993021214-A1 | ALPHA-AMINOBORONIC ACID PEPTIDES AND THEIR USE AS ELASTASE INHIBITORS | ZENECA LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| US-5254558-A | Substituted 1,3-diazines as leukocyte elastase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-19 | — | — | US | disclosed |
| US-5214152-A | Insecticides, miticides | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-05-25 | — | — | US | disclosed |
| EP-0529680-A2 | Intermediates, their production and their use for preparing alpha-unsaturated amines | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| EP-0528633-A1 | Pyrimidinyl acetamides as elastase inhibitors | ZENECA LIMITED (GB) | 1993-02-24 | — | — | EP | disclosed |
| US-5175301-A | Insecticide, miticide, pesticide | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-29 | — | — | US | disclosed |
| EP-0509559-A2 | Alpha-unsaturated amines, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-10-21 | — | — | EP | disclosed |
| EP-0509769-A2 | Heterocyclic amides having HLE inhibiting activity | ZENECA LIMITED (GB) | 1992-10-21 | — | — | EP | disclosed |
| CN-1031079-A | Alpha-unsaturated amines, process for their production and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1989-02-15 | — | — | CN | disclosed |
| EP-0302389-A2 | Alpha-unsaturated amines, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827620-B2 | Compounds and uses thereof for detection of target molecules in a sample | POLRMT, SNRPE, POLI | ACHE 4594/4885MEN1 2907/4885GAA 214/4885 |
| US-12421224-B2 | Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | UGGT1, MAN2A1, MAN2B2 | ACHE 889/4885MEN1 3434/4885GAA 6/4885 |
| US-12570666-B2 | Furoindazole derivatives | FURIN, CYP2F1, CYP3A7 | ACHE 3994/4885MEN1 426/4885GAA 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.